Outlook Therapeutics, Inc. (OTLK) Key Metrics
OTLK valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $118.9M
- Enterprise value
- $168.3M
- P/E (TTM)
- —
- Forward P/E
- 2.8
- PEG ratio
- —
- Price / sales
- 502.7
- Price / book
- 38.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.67
OTLK key metrics, FY2016–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsOTLK returns How much profit the business earns on the capital it uses.
Return on assets−16.8 pts
−263.4%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Asset turnover+971.3%
0.06
FY2025 · hover or tap a bar for each year
FY2016FY2025
OTLK financial health Debt, liquidity and how easily interest is covered.
Net debt+$7.3M
$22.1M
FY2025 · hover or tap a bar for each year
FY2016FY2025
Current ratio−41.1%
0.38
FY2025 · hover or tap a bar for each year
FY2016FY2025
Interest coverage
-236.9
FY2025 · hover or tap a bar for each year
FY2016FY2025
Debt / assets+57.5%
1.62
FY2025 · hover or tap a bar for each year
FY2016FY2025
OTLK efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+192 days
192 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Days payables outstanding−18,929 days
4,382 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Cash conversion cycle+19,927 days
-3,384 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Capex / revenue0.0 pts
0.0%
FY2025 · hover or tap a bar for each year
FY2016FY2025
OTLK returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
OTLK debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
OTLK cash returned to shareholders
DividendsBuybacksFree cash flow
OTLK key metrics
FY2016–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $1.06 | $5.34 | $4.42 | $24.40 | $43.40 | $14.40 | $29.80 | $156.80 | $219.20 | $680.00 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | −990.0% | — | — | — | — | — | — |
| Return on assets (ROA) | −263.4% | −246.6% | −193.9% | −257.3% | −249.9% | −191.2% | −175.2% | −139.9% | −174.8% | −301.9% |
| Return on tangible assets | −335.9% | −261.5% | −182.6% | −231.5% | −233.1% | −178.6% | −201.5% | −135.0% | −187.4% | −224.8% |
| Free cash flow margin | — | — | — | — | — | −543.1% | −401.8% | — | −414.4% | — |
| Financial health | ||||||||||
| Total debt | $30.2M | $29.7M | $35.6M | $11.0M | $11.9M | $8.8M | $14.9M | $21.9M | $18.4M | $8.7M |
| Cash & short-term investments | $8.1M | $14.9M | $23.4M | $17.4M | $14.5M | $12.5M | $8.0M | $1.7M | $3.2M | $2.4M |
| Net debt | $22.1M | $14.8M | $12.2M | −$6.4M | −$2.6M | −$3.7M | $6.9M | $20.2M | $15.2M | $6.4M |
| Debt / equity | — | — | — | 1.25 | 2.58 | 3.11 | — | — | — | — |
| Debt / assets | 1.62 | 1.03 | 1.10 | 0.38 | 0.52 | 0.45 | 0.87 | 0.98 | 0.89 | 0.37 |
| Current ratio | 0.38 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 | 0.67 | 0.10 | 0.14 | 0.28 |
| Quick ratio | 0.31 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 | 0.67 | 0.10 | 0.14 | 0.28 |
| Interest coverage | -236.9 | -22.7 | -21.0 | -42.4 | -55.3 | -19.9 | -10.5 | -7.6 | -6.4 | -27.7 |
| Working capital | −$28.4M | −$15.1M | −$15.8M | $7.8M | $14.8M | $2.1M | −$6.8M | −$28.7M | −$24.8M | −$14.8M |
| Invested capital | −$10.1M | −$58.3M | −$2.3M | $2.3M | $2.0M | −$912,144 | −$3.8M | −$596,931 | −$15.5M | $1.2M |
| Tangible asset value | −$32.2M | −$73.1M | −$14.4M | $8.7M | $4.6M | $2.8M | −$10.8M | −$20.8M | −$30.7M | −$5.2M |
| Net current asset value | −$33.4M | −$74.5M | −$15.8M | $7.7M | $3.3M | $1.0M | −$14.4M | −$39.8M | −$47.6M | −$23.2M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | $166.13B | $624.99B | $1.89T | $16.98B | — |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $1.1M | $0 | $72 |
| Capex / revenue | 0.0% | 0.0% | — | — | — | 0.0% | 5.4% | 90.1% | 7.7% | 36.9% |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.91 | 0.11 | 0.46 |
| Stock-based compensation / revenue | 629.5% | 3,165.4% | — | — | — | 48.0% | 16.1% | 64.3% | 224.9% | 417.8% |
| R&D / revenue | 1,965.3% | 24,548.6% | — | — | — | 450.0% | 292.2% | 599.2% | 624.6% | 1,099.4% |
| SG&A / revenue | 2,825.4% | 17,599.0% | — | — | — | 170.3% | 162.3% | 460.8% | 416.6% | 723.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 192.5 | 0.0 | — | — | — | 62.4 | 35.8 | 47.3 | 38.3 | — |
| Days of inventory on hand | 805.5 | — | — | — | — | — | — | — | — | — |
| Days payables outstanding | 4,382.2 | 23,310.8 | 41,573.4 | 5,071.1 | 3,196.3 | 1,539.1 | 45.1 | 143.6 | 122.8 | 45,525.9 |
| Cash conversion cycle (days) | -3,384.2 | -23,310.8 | — | — | — | -1,476.7 | -9.3 | -96.4 | -84.5 | — |
| Receivables turnover | 1.90 | — | — | — | 0.00 | 5.85 | 10.18 | 7.72 | 9.53 | — |
| Payables turnover | 0.08 | 0.02 | 0.01 | 0.07 | 0.11 | 0.24 | 8.09 | 2.54 | 2.97 | 0.01 |
| Inventory turnover | 0.45 | — | — | — | — | — | — | — | — | — |
| Asset turnover | 0.06 | 0.01 | 0.00 | 0.00 | 0.00 | 0.32 | 0.41 | 0.14 | 0.17 | 0.17 |
| Average receivables | $745,466 | $0 | — | — | $450,000 | $1.0M | $800,000 | $400,000 | $400,000 | — |
| Average payables | $9.1M | $7.3M | $5.0M | $2.8M | $2.3M | $2.3M | $2.9M | $7.3M | $8.0M | $4.1M |
| Average inventory | $1.7M | $0 | — | — | — | — | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from OTLK's annual financial statements (latest annual report filed December 19, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
OTLK valuation and financial ratios
It ended the year with $30.2 million of debt and $8.1 million in cash and short-term investments, net debt of $22.1 million.
See the OTLK income statement, the OTLK chart for price history, or the OTLK stock overview for the latest quote and news.
OTLK key metrics FAQ
How much debt does Outlook Therapeutics have?
Outlook Therapeutics had total debt of $30.2 million at the end of fiscal 2025.
What is Outlook Therapeutics's current ratio?
Outlook Therapeutics's current ratio was 0.38 at the end of fiscal 2025: current assets were 0.38 times current liabilities.